Clinical trial / 2006
Oral ellagic acid-rich pomegranate extract inhibited UV-induced decreases in skin luminance, indicating an inhibitory effect on slight skin pigmentation.
Thirty-nine healthy female volunteers were randomly assigned to receive high-dose pomegranate extract (200 mg/d ellagic acid), low-dose (100 mg/d), or placebo for 4 weeks. Following 1.5 MED of UV irradiation on the upper arm, decreases in L values from baseline were inhibited by 1.35% (low-dose) and 1.73% (high-dose) compared to control. In stratified analyses of subjects with slight sunburn, decreases in L values were significantly inhibited compared to control at weeks 1, 2 (p<0.01), and 4 (p<0.05) in the low-dose group, and at weeks 2 and 3 (p<0.05) in the high-dose group. Questionnaires showed ameliorating tendencies for items including 'brightness of the face' and 'stains and freckles.'
- Study type
- Double-blind, placebo-controlled randomized trial
- Who was studied
- 39 healthy female volunteers in their 20s to 40s (13 per group)
- What was measured
- Luminance (L), melanin, and erythema values after UV irradiation, and skin condition questionnaires
THE PAPER
Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin.
Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S. J Nutr Sci Vitaminol (Tokyo), 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.